Recurrent Soft Tissue Sarcoma Recruiting Phase 2 Trials for Erdafitinib (DB12147)

IndicationStatusPhase
DBCOND0105100 (Recurrent Soft Tissue Sarcoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03155620Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Screening